Condition
IIM
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (3)
P 2 (1)
Trial Status
Recruiting4
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06548620Early Phase 1Withdrawn
A Study of RD06-04 in Patients With Active Autoimmune Diseases
NCT06775912Early Phase 1Recruiting
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
NCT07374107Recruiting
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
NCT06991114Phase 2Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT07203404Early Phase 1Recruiting
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Showing all 5 trials